LUGANO, Switzerland - The Molecular Analysis for Precision oncology (MAP) Congress is designed to answer the critical question about how to integrate the wealth of information coming from the analysis of tumour samples into daily practice.
The programme will provide oncologists with expert guidance to seek and identify actionable mutations in patient’s DNA to provide the best possible personalised treatment.
- Molecular targeting
- Clonal evolution
- Mechanisms of IO toxicity
- Biomarkers for immunotherapeutics
- New technologies for therapeutic targeting
- ‘KRAS’ by Mariano Barbacid Montalbán, ES – 10 October at 12:00 CEST
To apply for media accreditation, please fill out the media registration form.
In addition to having access to sessions, live Q&A with invited speakers, e-poster area, virtual exhibition area, and industry satellite symposia, accredited journalists will also have access to the Meeting webcasts.
MAP Press Office
Notes to Editors
Please make sure to use the official name of the meeting in your reports: MAP 2020
Official Congress hashtag: #MAP20
ESMO is the leading professional organisation for medical oncology. With more than 25,000 members representing oncology professionals from over 160 countries worldwide, ESMO is the society of reference for oncology education and information. ESMO is committed to offer the best care to people with cancer, through fostering integrated cancer care, supporting oncologists in their professional development, and advocating for sustainable cancer care worldwide.
Founded in 1975, ESMO has European roots with a global reach. Home for all oncology stakeholders, ESMO connects professionals with diverse expertise and experience. Its education and information resources support an integrated multi-professional approach to cancer care, from a medical oncology perspective. ESMO seeks to erase boundaries in cancer care, whether between countries or specialities, and pursue its mission across oncology, worldwide.
Cancer Research UK (CRUK) is the largest independent funder of cancer research in Europe, and the world’s leading charity dedicated to cancer research. Today, 2 in 4 people survive their cancer for at least 10 years; Cancer Research UK’s ambition is to accelerate progress so that by 2034, 3 in 4 people will survive their cancer for at least 10 years. We fund high-calibre, innovative research that we believe has the potential to provide the greatest benefit to the public and cancer patients.
Our diverse portfolio spans a breadth of research areas, from fundamental discovery research to understand the biology and causes of cancer, through translational research to bring the latest discoveries to the benefit of patients, to drug discovery to identify potential new treatments, clinical research to deliver the best treatments for patients, and population-level research covering epidemiology, prevention and early detection of cancer.
We are proud to support 4,000 researchers, doctors and nurses in institutions across the UK and internationally. Our progress is dependent on these outstanding individuals and teams conducting high-quality research.
Unicancer is the only French hospital network 100% dedicated to the fight against cancer and the only national hospital federation dedicated to oncology. Unicancer is also the leading national academic sponsor of clinical trials in oncology in Europe. Its Research and Development Department is responsible for implementing its overall research strategy. She is ISO 9001 certified for her clinical research.
Key figures 2019: 18 French Cancer Comprehensive Centers (FCCC), private non-profit health establishments, spread over 20 hospital sites in France, also certified for their clinical research; 530,000 patients per year (short-stay, HAH and external procedures); 1/3 of French international publications in the field of oncology (source: bibliometric study/ Thomson Reuters); 100 active clinical trials promoted by Unicancer’s R&D, 46 of which are in recruitment, involving 6,257 patients included in 195 research centres, 24 of which are abroad; 57,000 patients registered in the ESME real life data programme.